SEC 13F Intelligence

Managers / Q1 2023 · view latest →

Birchview Capital, LP

CIK 0001618205 · 688 PINE STREET, SUITE D, C/O BIRCHVIEW CAPITAL, BURLINGTON, VT, 05401 · 802-923-3826

Reported Value
$127,725
Q1 2023
Positions
55
Filings on Record
39
2019–present window
Filed
May 12, 2023
original filing

Summary

Birchview Capital, LP reported $127,725 in U.S.-listed holdings across 55 positions for Q1 2023.

The portfolio is heavily concentrated: BMY alone accounts for 39.5% of reported value.

Compared with Q4 2022, the fund opened 3 new positions and exited 5.

Portfolio Metrics

Turnover
+4.3%
vs prior filed quarter
Top-10 Concentration
+76.6%
share of reported value
Largest Position
+39.5%
Bristol Myers Squibb
New / Exited
3 / 5
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $106MQ4 ’18Q1 ’19: $160MQ2 ’19: $164MQ3 ’19: $150MQ4 ’19: $138MQ4 ’19Q1 ’20: $113MQ2 ’20: $165MQ3 ’20: $150MQ4 ’20: $174MQ4 ’20Q1 ’21: $168MQ2 ’21: $167MQ3 ’21: $147MQ4 ’21: $155MQ4 ’21Q1 ’22: $139MQ2 ’22: $137MQ3 ’22: $142MQ1 ’23: $127,725Q1 ’23Q3 ’23: $117MQ4 ’23: $128MQ1 ’24: $122MQ2 ’24: $108MQ2 ’24Q3 ’24: $115MQ4 ’24: $123MQ1 ’25: $115MQ2 ’25: $101MQ2 ’25Q3 ’25: $132MQ4 ’25: $171MQ1 ’26: $176Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 84.1%Other: 15.9%
  • Common Stock · 84.1% · $107,418
  • Other · 15.9% · $20,307

Quarter-over-Quarter Changes full breakdown →

vs Q4 2022 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
TVTXTRAVERE THERAPEUTICS INCNEW+30.0K30.0K+$675$675
CHINOOK THERAPEUTICS INCNEW+15.0K15.0K+$347$347
PGNYPROGYNY INCNEW+9.0K9.0K+$289$289
BLUEBIRD BIO INCADDED+101.2K199.2K−$45$633
BDQMALBIREO PHARMA INCSOLD OUT−117.0K0−$2,528$0
AVEO PHARMACEUTICALS INCSOLD OUT−100.0K0−$1,495$0
CNCEEURCONCERT PHARMACEUTICALS INCSOLD OUT−20.0K0−$117$0
BIOHAVEN PHARMACEUTICAL HOLDING CO LTDSOLD OUT−7.4K0−$102$0

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2023

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1BMYBRISTOL-MYERS SQUIBB COhistory →COM39.54%$50,498728.6K
2BIODESIX INCCOM7.34%$9,3745.04M
3NBIXNEUROCRINE BIOSCIENCES INChistory →COM6.68%$8,52784.2K
4PROTHENA CORP PLCSHS4.87%$6,223128.4K
5QDEL*QUIDELORTHO CORPhistory →COM4.28%$5,46261.3K
6ACADACADIA PHARMACEUTICALS INChistory →COM3.68%$4,694249.4K
7HROWHARROW HEALTH INChistory →COM2.98%$3,809180.0K
8UTHUNITED THERAPEUTICS CORPhistory →COM2.63%$3,35915.0K
9OVVOVINTIV INChistory →COM2.38%$3,03884.2K
10MASI*MASIMO CORPhistory →COM2.21%$2,82015.3K
11PHRPHREESIA INChistory →COM2.09%$2,67082.7K
12ELUTAZIYO BIOLOGICS INChistory →COM1.96%$2,4991.66M
13FHTXFOGHORN THERAPEUTICS INChistory →COM1.29%$1,642264.8K
14ACCELERATE DIAGNOSTICS INCCOM1.23%$1,5772.25M
15ALKERMES PLCSHS1.10%$1,41050.0K
16INBXUSDINHIBRX INChistory →COM1.04%$1,32970.4K
17ATECALPHATEC HOLDINGS INCCOM0.98%$1,24880.0K
18KPTIEURKARYOPHARM THERAPEUTICS INCCOM0.89%$1,133291.3K
19HTDCORCEPT THERAPEUTICS INCCOM0.85%$1,08350.0K
20DCGODOCGO INCCOM0.75%$952110.0K
21VTYXUSDVENTYX BIOSCIENCES INCCOM0.69%$88426.4K
22CYTKCYTOKINETICS INCCOM0.69%$88025.0K
23PTGXPROTAGONIST THERAPEUTICS INCCOM0.68%$87438.0K
24APLSUSDAPELLIS PHARMACEUTICALS INCCOM0.62%$79212.0K
25PXDEURPIONEER NATURAL RESOURCES COCOM0.61%$7763.8K
26ETRNUSDEQUITRANS MIDSTREAM CORPORATIOCOM0.60%$769133.1K
27TVTXTRAVERE THERAPEUTICS INCCOM0.53%$67530.0K
28BLUEBIRD BIO INCCOM0.50%$633199.2K
29TSVT*2SEVENTY BIO INCCOM0.48%$61059.8K
30OPHTEURIVERIC BIO INCCOM0.48%$60825.0K
31IMGNEURIMMUNOGEN INCCOM0.45%$576150.0K
32TXG10X GENOMICS INCCL A COM0.44%$55810.0K
33SOLENO THERAPEUTICS INCCOM0.41%$525245.1K
34ARVNARVINAS INCCOM0.32%$41015.0K
35SILKUSDSILK ROAD MEDICAL INCCOM0.31%$39110.0K
36HALOHALOZYME THERAPEUTICS INCCOM0.30%$38210.0K
37XENEXENON PHARMACEUTICALS INCCOM0.28%$35810.0K
38CHINOOK THERAPEUTICS INCCOM0.27%$34715.0K
39SRPTSAREPTA THERAPEUTICS INCCOM0.27%$3452.5K
40XNCRXENCOR INCCOM0.27%$34312.3K
41KINIKSA PHARMACEUTICALS LTDCOM0.25%$32330.0K
424XC1KALVISTA PHARMACEUTICALS INCCOM0.25%$31440.0K
43AM6AMICUS THERAPEUTICS INCCOM0.24%$31128.0K
44KROSKEROS THERAPEUTICS INCCOM0.23%$2997.0K
45PGNYPROGYNY INCCOM0.23%$2899.0K
46CGEMCULLINAN ONCOLOGY INCCOM0.20%$25725.1K
47BCRXBIOCRYST PHARMACEUTICALS INCCOM0.13%$16720.0K
48INFLARX NVCOM0.11%$13670.0K
49STOKSTOKE THERAPEUTICS INCCOM0.10%$12515.0K
50GOSSGOSSAMER BIO INCCOM0.10%$12599.1K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$176M73May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$171M68Feb 13, 202613F-HRchanges · EDGAR ↗
Q3 2025$132M69Nov 13, 202513F-HRchanges · EDGAR ↗
Q2 2025$101M71Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$115M68May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$123M68Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$115M62Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$108M61Aug 13, 202413F-HRchanges · EDGAR ↗
Q1 2024$122M60May 14, 202413F-HRchanges · EDGAR ↗
Q4 2023$128M59Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$117M52Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023Under review54Aug 8, 202313F-HRchanges · EDGAR ↗
Q1 2023$127,72555May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022Under review57Feb 3, 202313F-HRchanges · EDGAR ↗
Q3 2022$142M60Nov 28, 2022RESTATEMENTchanges · EDGAR ↗
Q2 2022$137M64Aug 12, 202213F-HRchanges · EDGAR ↗
Q1 2022$139M63May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$155M67Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$147M64Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$167M62Aug 10, 202113F-HRchanges · EDGAR ↗
Q1 2021$168M54May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$174M48Feb 9, 202113F-HRchanges · EDGAR ↗
Q3 2020$150M50Nov 12, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$165M51Aug 10, 202013F-HRchanges · EDGAR ↗
Q1 2020$113M46May 12, 202013F-HRchanges · EDGAR ↗
Q4 2019$138M52Feb 12, 202013F-HRchanges · EDGAR ↗
Q3 2019$150M50Nov 12, 201913F-HRchanges · EDGAR ↗
Q2 2019$164M54Aug 6, 201913F-HRchanges · EDGAR ↗
Q1 2019$160M54May 3, 201913F-HRchanges · EDGAR ↗
Q4 2018$106M52Feb 6, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.